Janssen Pharmaceuticals, a pharmaceutical company of Johnson & Johnson, has announced an expanded policy on improved accessibility of medicines in which the geographic scope of its earlier 2012 policy of waiving enforcement of patent rights for pediatric formulations of Darunavir, is expanded. This expansion includes many low and middle income countries including India, Pakistan and Sri Lanka. The company has further committed itself to providing technical expertise to Pediatric HIV Treatment Initiative (PHTI) on developing a fixed-dose combination of Darunavir boosted with ritonavir (DRV/r).
top of page
Search
Recent Posts
See AllGeneral Motors has secured an Indian patent on a hybrid powertrain control system for vehicles. The patent rights are currently assigned...
Taking into consideration the Delhi High court’s order staying the abandonment orders passed by the Trademarks Office, the Registrar of...
The order of the Delhi High Court allows the Competition Commission of India (CCI) to attend to complaints on abuse of dominance of...
bottom of page
Comments